2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effects
2011
Control of antiviral immunity by pattern recognition and the microbiome
Pang IK, Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunological Reviews 2011, 245: 209-226. PMID: 22168422, PMCID: PMC3659816, DOI: 10.1111/j.1600-065x.2011.01073.x.Peer-Reviewed Original ResearchConceptsAdaptive immunityInnate pattern recognition receptorsChronic viral infectionsAdaptive immune responsesExtra-intestinal infectionsHost immune systemPattern recognition receptorsTransduce signalsImmune activationAutoimmune diseasesProbiotic therapyMammalian hostsImmune responseAntiviral immunityViral infectionMucosal surfacesViral recognitionImmune systemInvasive microbesProper developmentMicrobial sensingResident microbiotaInnate defenseSuch diseasesHost susceptibility